Top Industry News

Mallinckrodt and Endo, two specialty pharma and generics companies, have agreed to merge in a stock-and-cash transaction in a deal valued at $6.7 billion. The companies made the announcement earlier…

AstraZeneca has announced an investment of $2.5 billion in Beijing to establish its sixth global strategic R&D center and has also announced research and manufacturing agreements that will further advance…

Roche has entered into an exclusive collaboration and licensing agreement with Zealand Pharma, a Søborg, Denmark-based bio/pharmaceutical company, to co-develop and co-commercialize petrelintide, an obesity drug, in a deal worth…

The latest from CDMOs, CMOs, and suppliers featuring Delpharm, Almac Group, Singota, Enzene and Benuvia Operations. Chemicals/Chemical API Manufacturing* CordenPharma Investing $536-M in New Peptide Mfg Facility in SwitzerlandBiologics Manufacturing*…

A roundup of manufacturing news from Chiesi and Entos Pharmaceuticals. Highlights below. * Chiesi Investing $464 M for Inhaler Mfg Facility* Entos Plans New R&D and Biomanufacturing Facility for Nucleic-Acid Based…

A roundup of bio/pharmaceutical partnering news from Novo Nordisk/United Bio-Technology (Hengqin), Merck & Co./Hengrui Pharma, Roche/Oxford BioTherapeutics, AstraZeneca/Alteogen, and BI/Salipro Biotech. Highlights below.   * Novo Nordisk in $2-Bn Licensing Pact…

The latest news on mergers and acquisitions featuring Sanofi/Dren Bio, Taiho Pharmaceutical/Araris Biotech, AstraZeneca/EsoBiotec and Bristol Myers Squibb/2seventy bio. Highlights below. * Sanofi To Acquire Bispecific Antibody from Dren Bio…

Eli Lilly and Company has announced plans to bolster its domestic medicine production by building four new pharmaceutical manufacturing sites in the US. This new investment brings the company’s total…

Thermo Fisher Scientific has agreed to acquire the purification and filtration business of Solventum, a Saint Paul, Minnesota-based healthcare company, for $4.1 billion.  Solventum, which was spun off from 3M…

GSK has completed its acquisition of IDRx, a Boston-based, clinical-stage bio/pharmaceutical company, in a deal worth up to $1.1 billion ($1 billion upfront and $150 million in milestone payments). The…